Scholarlink

Purpose <p>While prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a highly sensitive modality for staging prostate cancer, a notable subset of patients presents with negative findings, leading to potential under-diagnosis. The incremental diagnostic value of multiparametric magnetic resonance imaging (mpMRI) in this specific cohort remains poorly defined. This study aimed to evaluate the added value of mpMRI in newly diagnosed prostate cancer patients with negative PSMA PET/CT results and to identify patient characteristics that predict this benefit.</p> Methods <p>This retrospective study included 200 patients with newly diagnosed, treatment-naïve prostate cancer who underwent both <sup>68</sup>&#xa0;Ga-PSMA-11 PET/CT and pelvic mpMRI between June 2018 and September 2021. We identified patients with negative <sup>68</sup>&#xa0;Ga-PSMA-11 PET/CT findings but positive mpMRI results (PSMA-/MRI +). The clinicopathological characteristics, including Prostate-Specific Antigen (PSA) levels and Gleason scores, of the PSMA-/MRI + group were compared with the rest of the cohort. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of PSMA-/MRI + status.</p> Results <p>Of the 200 patients, 18 presented with negative <sup>68</sup>&#xa0;Ga-PSMA-11 PET/CT findings. Among 18 patients with negative <sup>68</sup>&#xa0;Ga-PSMA-11 PET/CT scans, mpMRI successfully detected lesions in 17 (94.4%). These PSMA-/MRI + findings were validated as true positives by histopathology, follow-up imaging, or PSA response to therapy. Patients in the PSMA-/MRI + group exhibited significantly lower PSA levels (mean, 22.6 vs. 60.0&#xa0;ng/mL; <i>P</i> = 0.002) and lower Gleason scores (median, 7 [6, 9] vs. 7 [7, 9]; <i>P</i> = 0.013). Multivariate analysis confirmed that both a lower PSA level (OR, 0.117; 95% CI, 0.024–0.566; <i>P</i> = 0.008) and a lower Gleason score (OR, 0.218; 95% CI, 0.060–0.787; <i>P</i> = 0.020) were independent predictors of PSMA-/MRI + findings. Patients with both low PSA (&lt; 24.05&#xa0;ng/mL) and low Gleason score (&lt; 7) had the highest detection rate of PSMA-/MRI + lesions (37.5%, <i>P</i> &lt; 0.001).</p> Conclusion <p>Multiparametric MRI provides significant added diagnostic value in detecting prostate cancer in newly diagnosed patients with negative <sup>68</sup>&#xa0;Ga-PSMA-11 PET/CT results. This complementary role is particularly pronounced in patients with lower PSA levels and Gleason scores. Integrating mpMRI into the diagnostic pathway for this subgroup can mitigate the risk of under-staging and improve clinical decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Beyond PSMA: The essential complementary role of MRI in staging prostate cancer with Low-PSMA expression phenotypes

  • 期刊论文

  • 发表日期：

    2025年10月20日

查看全文
  • Ruohua Chen,
  • Yining Wang,
  • Liang Dong,
  • Haitao Zhao,
  • Lianghua Li,
  • Gang Huang,
  • Liu Liu,
  • Jianjun Liu

摘要

Purpose

While prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a highly sensitive modality for staging prostate cancer, a notable subset of patients presents with negative findings, leading to potential under-diagnosis. The incremental diagnostic value of multiparametric magnetic resonance imaging (mpMRI) in this specific cohort remains poorly defined. This study aimed to evaluate the added value of mpMRI in newly diagnosed prostate cancer patients with negative PSMA PET/CT results and to identify patient characteristics that predict this benefit.

Methods

This retrospective study included 200 patients with newly diagnosed, treatment-naïve prostate cancer who underwent both 68 Ga-PSMA-11 PET/CT and pelvic mpMRI between June 2018 and September 2021. We identified patients with negative 68 Ga-PSMA-11 PET/CT findings but positive mpMRI results (PSMA-/MRI +). The clinicopathological characteristics, including Prostate-Specific Antigen (PSA) levels and Gleason scores, of the PSMA-/MRI + group were compared with the rest of the cohort. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of PSMA-/MRI + status.

Results

Of the 200 patients, 18 presented with negative 68 Ga-PSMA-11 PET/CT findings. Among 18 patients with negative 68 Ga-PSMA-11 PET/CT scans, mpMRI successfully detected lesions in 17 (94.4%). These PSMA-/MRI + findings were validated as true positives by histopathology, follow-up imaging, or PSA response to therapy. Patients in the PSMA-/MRI + group exhibited significantly lower PSA levels (mean, 22.6 vs. 60.0 ng/mL; P = 0.002) and lower Gleason scores (median, 7 [6, 9] vs. 7 [7, 9]; P = 0.013). Multivariate analysis confirmed that both a lower PSA level (OR, 0.117; 95% CI, 0.024–0.566; P = 0.008) and a lower Gleason score (OR, 0.218; 95% CI, 0.060–0.787; P = 0.020) were independent predictors of PSMA-/MRI + findings. Patients with both low PSA (< 24.05 ng/mL) and low Gleason score (< 7) had the highest detection rate of PSMA-/MRI + lesions (37.5%, P < 0.001).

Conclusion

Multiparametric MRI provides significant added diagnostic value in detecting prostate cancer in newly diagnosed patients with negative 68 Ga-PSMA-11 PET/CT results. This complementary role is particularly pronounced in patients with lower PSA levels and Gleason scores. Integrating mpMRI into the diagnostic pathway for this subgroup can mitigate the risk of under-staging and improve clinical decision-making.